The Proliferation And Apoptosis Ability Of Bone Marrow CD71~+?CD235a~+ Nucleated Cell In Patients With Chronic Mountain Sickness

Objective To study the proliferation and apoptosis ability of bone marrow CD71+?CD235a+nucleated cell in patients with CMS.And study effect of PD98059,a specific inhibitor of Ras/Raf/MEK/ERK signaling pathway, on the proliferation and apoptosis ability of bone marrow CD71+?CD235a+ nucleated cells in patients with CMS and the pathogenesis of CMS.Methods The CD71+?CD235a+ nucleated cells in CMS patients and control(patients with simple obsolete stracture) were sorted by using the immune-magnetic beads,divided into adding inhibitor and without inhibitor groups. Adding with 5, 10, 20 ?mol/L of PD98059 and DMSO(as control) in adding inhibitor group. Both of the two were cultured 72 h under hypoxia.The cell apoptosis was detection by flow cytometry with Annexin V and PI double staining, the cell proliferation was detection by CCK-8 method; Colony forming experiment observation of CD71+?CD235a+ nucleated cells and BMMNCs clone formation ability.Results(1) Bone marrow CD71+?CD235a+ nucleated cell apoptosis ratio in patients with CMS is lower than Control(P<0.05).With the increase of PD98059 the apoptosis rate of bone marrow CD71+?CD235a+ nucleated cell in CMS patients increased(r=0.807,P<0.01).(2) Bone marrow CD71+?CD235a+ nucleated cell proliferation ratio in patients with CMS increased(P<0.05).With the increase of PD98059 the proliferation inhibition rate of bone marrow CD71+?CD235a+ nucleated cell in CMS patients increased(r=-0.305, P<0.01).Hemoglobin has no significant correlation with the degree of the cell proliferation,(r=0.014, P=0.967).(3) Bone marrow CD71+?CD235a+ nucleated cell in CMS cluster formation rate in 7 and14 days, there was no statistically significant difference compared with Control(P>0.05).(4) BMMNCs in CMS group compared with the Control group in 7and 14 days colony formation rate is higher than the Control group(P<0.05). With the increase of PD98059 BMMNCs erythroid colony formation in patients with CMS decrease(r=-0.405,P<0.01).It was statistically significant in 7 days and 14 days(P<0.05).Conclusion(1) Bone marrow CD71+?CD235a+ nucleated cell in CMS patients proliferation increased and apoptosis decreased.(2) The MEK specific inhibitor PD98059 can inhibit the proliferation and promote apoptosis of CD71+?CD235a+ nucleated cell in CMS patients. The PD98059 can also inhibition the excessive accumulation of erythrocytes.